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Background-—Cardiovascular morbidity and mortality was reduced by 25% when blood pressure (BP) was targeted to 120 mm Hg
systolic compared with 140 mm Hg systolic in Systolic Blood Pressure Intervention Trial (SPRINT); however, BP was measured
using a research technique. SPRINT specified 5 minutes of seated rest in a quiet room followed by 3 oscillometric measurements
without an observer in the room. The relationship of this research-grade methodology to routine BP measurements is not known.
Methods and Results-—Among 275 people with chronic kidney disease who had BP <140/90 mm Hg when they came to the
clinic, we measured BP as in SPRINT and recorded BP on the same day without specification of seated rest. Compared with routine
measurement, the research-grade systolic BP was 12.7 mm Hg lower with wide limits of agreement (46.1 to 20.7 mm Hg).
Research grade systolic BP was 7.9 mm Hg lower than daytime ambulatory systolic BP and had wide agreement limits (33.2 to
17.4 mm Hg). Whereas the routine, research-grade, and daytime ambulatory systolic BP were all related to echocardiographic left
ventricular hypertrophy, the strength of the relationship between research-grade and daytime ambulatory systolic BP to
left ventricular hypertrophy was similar and stronger than the strength of the relationship between routine systolic BP and left
ventricular hypertrophy.
Conclusions-—Taken together, these results suggest that translation of the SPRINT results will require measurement of BP as
performed in that trial. Instead of an algebraic manipulation of routine clinic measurements, the SPRINT methodology of BP
measurement would be needed at minimum if implementation of the SPRINT results were to be deployed in the population at large.
( J Am Heart Assoc. 2017;6:e004536. DOI: 10.1161/JAHA.116.004536.)
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T here has been much debate in recent years about whatthe treatment targets should be for blood pressure (BP)
control among hypertensive people.1 Whereas the current
guidelines recommend a BP target of <140/90 mm Hg
among those with hypertension, the recently released results
of Systolic Blood Pressure Intervention Trial (SPRINT) chal-
lenge this notion.2 The results of SPRINT showed that when
BP was targeted to <120 mm Hg, compared with a higher
target of 140 mm Hg, the hazard ratio for cardiovascular
morbidity and mortality was reduced by 25%.2 What has
received scarce attention is that the method of measuring BP
in SPRINT was, as expected, research grade. Measurement
was performed after a mandatory seated rest in a quiet room
for 5 minutes, after which 3 recordings were made at
1-minute intervals.3 No observer was present in the room
during the measurement. The average of these recordings was
used to target BP in the participants. In the office setting, BP
recordings using meticulous methods such as those recom-
mended by the guidelines and those used in SPRINT are often
not made. Accordingly, it remains unclear whether the BP
targets used in SPRINT can be implemented in the general
population if routine methods of BP measurement are used.
In this study, we measured BP with the methodology used
in SPRINT and compared the value with a single measurement
taken without specification for 5-minute rest and using a
validated device. We reported the agreement between the 2
methods and the relationship of each of these 2 methods with
the reference standard of 24-hour ambulatory BP recordings.
Furthermore, we tested the strength of the association of
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each of these 3 methodologies with target organ damage
measured using echocardiographic left ventricular hypertro-
phy (LVH).
Methods
Participants were recruited from a renal clinic and a general
medicine clinic at the Richard L Roudebush Veterans Affairs
Medical Center in Indianapolis, Indiana, as detailed previously
in a report.4 To participate, patients had to have BP measured
in the clinic on the day of recruitment, BP in the normotensive
range (<140/90 mm Hg), and evidence of chronic kidney
disease. We excluded those with kidney transplantation or
dialysis and those receiving immunosuppressive drugs.
After obtaining signed informed consent, participants were
invited to our research laboratory. This typically occurred in a
fasting state and in the morning. BP measurement was
performed using the Omron HEM 907 oscillometric monitor
(Omron Healthcare) with a cuff size appropriate for the arm.
This device has been validated by several investigators using
standardized protocols.5,6 The monitor was programmed such
that the cuff did not start to inflate until the participant rested
quietly for 5 minutes in a seated position with the arm at the
level of the heart. Three consecutive recordings were made
30 seconds apart. Although 1-minute intervals were used in
SPRINT, 30-second intervals have been widely used in the
National Health and Nutrition Examination Survey.7 The
average of these 3 recordings was called research-grade
clinic BP. No observer was present in the room during these
measurements. This technique is similar to that reported in
SPRINT.
Two-dimensional guided M-mode echocardiograms were
performed by an accredited technician with a digital cardiac
ultrasound machine (Cypress Acuson; Siemens Medical).8 The
protocol specified recording of at least 12 cycles of
2-dimensional parasternal long- and short-axis left ventricular
(LV) views with optimal orientation of the cursor beam to
derive additional M-mode recordings. Each patient underwent
6 M-mode measurements of interventricular septal thickness
in diastole (IVSTd), LV internal diameter in diastole (LVIDd)
and systole, LV posterior wall thickness in diastole (LVPWd)
and systole, and left atrial diameter using standards of the
American Society of Echocardiography.9 LV mass was calcu-
lated using a previously validated formula10: LV mass (g)
=0.8329[(IVSTd+LVIDd+PWTd)3(LVIDd)3]+0.60. LVH was
diagnosed if LV mass was ≥104 g/m2 among women and
≥116 g/m2 among men.
Following the echocardiogram, another BP was obtained
using a validated device (Omron HEM 705 CP; Omron
Healthcare).11 This measurement, however, was made only
once by the echocardiographer who was present in the room
at the time of the measurement. The participant was in the
supine position during the measurement. We called this
routine clinic measurement.
All participants then underwent 24-hour ambulatory BP
monitoring using the validated Spacelabs 90207 device,12 as
reported previously.4 Participants kept diaries that were used
to calculate sleep and wake times. Each participant’s medical
record was reviewed to ascertain underlying comorbid
illnesses. The reported comorbidities are those established
after review of the medical record.
Means and standard deviations are reported for continuous
data, and frequency and percentages are reported for discrete
data. To calculate agreement between routine and research-
grade BP measurement or between each of these 2 methods
and ambulatory BP recordings, the methods proposed by
Bland and Altman were used.13 The relationship of each of
these 3 methods with LVH was established using logistic
regression analysis. Outcome was LVH as a dichotomous
variable. The sole predictor variable was the BP of interest.
Models were not adjusted for multiple comparisons. Likeli-
hood ratios in nested models were used to test the goodness
of fit. Better goodness of fit indicated greater strength of
association. Subgroup analyses for Bland–Altman analyses
were made, and interaction effects of the variable were
reported as follows: The outcome was the difference between
research-grade BP and either usual BP (Figure S1) or daytime
ambulatory BP (Figure S2). In a linear regression model, the
subgroup of interest was used as an indicator variable. The P
value of this estimate was reported as the interaction effect.
Alpha was set at 0.05, and P values were 2-sided. All analyses
were done for 275 patients. All patients had complete data on
research-grade, usual, and ambulatory BP.
The study was approved by the institutional review board,
and all participants provided written informed consent.
Results
Table 1 shows the baseline characteristics of the 275
participants. Of the 333 participants recruited, 275 had
echocardiograms that form the basis of this report. Ages
ranged from 38 to 89 years, 65% of the participants were aged
≥65 years, and 32% were aged ≥75 years. There was diversity
in race with 17% of participants being black; however, 98% of
participants were men. About 65% had underlying diabetes
mellitus, and there was a high prevalence of cardiovascular
disease; for example, approximately a fifth each had coronary
artery bypass grafting, peripheral vascular disease, or a prior
hospitalization for heart failure. The distribution of chronic
kidney disease stages was as follows: 5% stage 3A, 35% stage
3B, 52% stage 4, and 7% stage 5. Only 2 participants had an
estimated glomerular filtration rate >60 mL/min per 1.73 m2.
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Albuminuria stage 2 (albumin/creatinine ratio >300 mg/g
creatinine) was present in 22%, stage 1 (albumin/creatinine
ratio 30–300 mg/g creatinine) was present in 27%, and 51%
had no albuminuria. Of the 275 participants, 269 (98%) were
being treated with antihypertensive drugs; the mean number
of antihypertensive medications was 3.1.
Figure 1 shows the Bland–Altman plots. On average,
compared with routine clinic BP, research-grade systolic BP
was 12.7 mm Hg lower and diastolic BP was 12.0 mm Hg
lower. Notably, both measurements were recorded on the
same day in each participant. The limits of agreement for
systolic BP (46.1 to 20.7 mm Hg) and diastolic BP (34.2
to 10.1 mm Hg) were wide. Subgroup analyses are shown in
Figure S1. Results indicate that bias and limits of agreement
were not influenced by any one subgroup.
Table 2 and Figure 1 show the relationship of research-
grade, routine clinic, and daytime ambulatory BP for all
participants. Research-grade systolic and diastolic BP were
both lower than the corresponding daytime ambulatory BP.
The systolic research-grade clinic BP was 7.9 mm Hg lower
(95% CI 9.4 to 6.4 mm Hg), and diastolic research grade
clinic BP was 11.7 mm Hg lower (95% CI 12.7 to
10.8 mm Hg). In contrast, routine clinic BP was 4.8 mm Hg
higher systolic and 0.3 mm Hg higher diastolic; however, for
diastolic BP, the difference was not significantly different from
zero.
Analyses in 10 subgroups indicated that bias (difference
between research-grade systolic BP and daytime ambulatory
systolic BP) was not modified by 8 of 10 subgroups
(Figure S2). Nevertheless, both diabetes mellitus (P=0.01)
and marginally peripheral vascular disease (P=0.06) influ-
enced bias. Compared with daytime ambulatory systolic BP,
the research-grade systolic BP was 4.8 mm Hg lower in
those without diabetes mellitus and 9.6 mm Hg lower in
those with diabetes mellitus. Compared with daytime
ambulatory systolic BP, the research-grade systolic BP was
8.7 mm Hg lower in those without peripheral vascular
disease and 5 mm Hg lower in those with peripheral
vascular disease; however, the limits of agreement remained
similarly wide.
To further explore the association of routine clinic and
research-grade clinic BP measurements, we calculated the
odds of echocardiographic LVH with each type of BP
measurement. Figure 2 shows the odds ratios for each type
of systolic BP measured in this analysis. The strength of the
association of LVH and systolic BP was greater for ambulatory
and research-grade measurements compared with routine
clinic measurements.
Discussion
The major findings of this study are that research-grade BP
recordings are substantially lower than routinely measured
single recordings in the clinic. The limits of agreement
between these 2 recordings are wide and cannot be predicted
by any one factor. Finally, the relationship of routine clinic
recordings to target organ damage measured by
Table 1. Baseline Characteristics of the Study Sample
Variable Result (n=275)
Age, y 69.210.1
Male sex, n (%) 269 (98)
Race
White, n (%) 220 (80)
Black, n (%) 47 (17)
Other, n (%) 8 (3)
Body mass index, kg/m2 30.94.7
Comorbid illnesses
Diabetes mellitus, n (%) 180 (65)
Myocardial infarction, n (%) 77 (28)
Percutaneous coronary revascularization, n (%) 73 (27)
Coronary artery bypass grafting, n (%) 57 (21)
Congestive heart failure, n (%) 50 (18)
Stroke, n (%) 34 (12)
Peripheral vascular disease, n (%) 58 (21)
Current smoker, n (%) 42 (15)
Estimated glomerular filtration rate, mL/min/1.73 m2 28.610.2
Antihypertensive drugs, n 3.11.4
Angiotensin-converting enzyme inhibitors, n (%) 143 (52)
Angiotensin receptor blockers, n (%) 60 (22)
Beta blockers, n (%) 187 (68)
Dihydropyridine calcium channel blockers, n (%) 121 (44)
Loop diuretics, n (%) 104 (38)
Thiazide diuretics, n (%) 67 (24)
Blood pressure measurements
Research-grade systolic 121.717.9
Research-grade diastolic 59.711.7
Routine clinic systolic 134.519.5
Routine clinic diastolic 71.812.8
24-hour ambulatory systolic 126.914.3
24-hour ambulatory diastolic 69.19.2
Nighttime ambulatory systolic 122.316.3
Nighttime ambulatory diastolic 65.210.1
Daytime ambulatory systolic 129.614.3
Daytime ambulatory diastolic 71.59.3
Data are shown as meanSD except as noted.
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echocardiographic recordings is weaker compared with
research-grade or ambulatory BP recordings.
In the intensive treatment group, the mean systolic BP over
a 3.26-year average follow-up in SPRINT was 121.5 mm Hg;
this was achieved with the use of 2.8 medications. The mean
systolic research-grade BP in our study was 121.7 mm Hg,
and this was achieved with the use of 3.1 medications.
Consequently, the 2 populations are comparable, at least with
respect to achieved BP and antihypertensive medications.
Research-grade BP was 12.7/12.0 mm Hg lower compared
with routine clinic BP. Adding 12.7 mm Hg to the target BP of
120 mm Hg systolic measured in SPRINT yields
132.7 mm Hg systolic. This may be considered the “routine
BP goal”: however, this would be a na€ıve approach, given that
the limits of agreement between measurements were wide.
As an example, for a target BP of 120 mm Hg systolic
measured using research-grade methodology, patients may
have differences from routine clinic BP that may be
46.1 mm Hg lower or 20.7 mm Hg higher, making such
recommendations worthless.
Contrary to the popular belief that clinic BP is always
higher, on average, the research--grade systolic and diastolic
BP was considerably lower than daytime ambulatory BP.
Systolic BP was 7.9 mm Hg lower and diastolic BP was
11.7 mm Hg lower. In comparison, the routine clinic BP was,
on average, 4.8 mm Hg higher systolic and no different from
diastolic BP. Neither the research-grade BP nor the routine
clinic BP was able to estimate daytime ambulatory BP
accurately; the agreement limits for each measure were
wide. Even among participants without diabetes mellitus or
with peripheral vascular disease, for which the bias was lower,
the limits of agreement remained wide. Consequently, neither
of the 2 measurements is an adequate replacement for
ambulatory BP measurement.
The recently released Canadian Hypertension and Educa-
tion Program guidelines recommend the use of automated
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Figure 1. Bland–Altman plot showing the mean differences between various blood pressure (BP) recordings and their limits of agreement. The
top panel shows systolic BP and the bottom panel shows diastolic BP. Research-grade BP was, on average, 12.7/12.0 mm Hg lower (bias) than
routine clinic BP and had wide limits of agreement.
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office BP recordings without an observer in the room.14 These
guidelines, however, do not mandate the 5-minute period of
rest that is specified in SPRINT14; therefore, the automated
office BP recordings are not synonymous with measurements
made in SPRINT. Nonetheless, recordings made using an
automated device are often much lower than routine
measurements,15,16 and the agreement limits are wide.15
These findings are similar to what we reported in this study;
however, in contrast to the observation that the automated
office BP recording is similar to daytime ambulatory BP,17 we
noted that the research-grade BP was substantially lower than
daytime ambulatory BP with wide agreement limits.
SPRINT excluded people with diabetes mellitus. The
ACCORD (Action to Control Cardiovascular Risk in Diabetes)
study randomized patients with diabetes mellitus who were
hypertensive to the same systolic BP targets as those used in
SPRINT.18 The sample size of ACCORD was less than half that
of SPRINT, and a factorial design included interventions to
test lipid lowering with fenofibrate and intensive or standard
glucose lowering. The hazard ratio for the primary end point
was 0.89, favoring intensive BP lowering. Furthermore, there
was 48% reduction in relative risk for stroke. Although the
ACCORD study used the same automated device as SPRINT
(Omron HEM 907) and measured BP in triplicate at each visit,
it is less clear whether ACCORD required and enforced a
mandatory period of 5 minutes of rest and whether the
readings were observed or unobserved (supplementary
appendix 2 of Cushman et al18). The overall results of the
ACCORD trial for intensive BP lowering, providing little
additional benefit for cardiovascular end points, could be
partly related to the cointerventions of lipid and glucose
lowering, which may have diluted the results of aggressive BP
lowering. It is possible, however, that the BP measurement
methodology could be operative.
SPRINT excluded people with stroke. Patients with recent
lacunar strokes were randomized to intensive (target systolic
BP <130 mm Hg) or standard (target systolic BP
<140 mm Hg) groups and followed for an average of
3.7 years in the SPS3 (Secondary Prevention of Small
Subcortical Strokes) study.19 The more intensive treatment
reduced the rate of recurrent stroke by 19% (P=0.08) and the
rate of intracerebral hemorrhage by 63% (P=0.03). In this
study, the Colin 8800C electronic device was used (Colin
Medical Instruments) to measure BP in triplicate after
15 minutes of sitting quietly in a seated position; BP was
measured at 2-minute intervals in the right arm (unless the
left arm had 10-mm Hg higher systolic BP).20 These BP
recordings were obtained with an observer in the room.
Whether the study mandated and enforced 15 minutes of
quiet rest prior to cuff inflation is not clear. Aside from the
smaller difference in BP targets in SPS3 compared with
SPRINT, the measurement technique may have made a
difference in outcomes.
Table 2. Agreement Assessed With the Bland–Altman Method Using the 3 Blood Pressure Measurement Techniques
Variable Bias (95% CI) Limits of Agreement
Research grade, routine SBP 12.7 (14.7 to 10.7) 46.1 to 20.7
Research grade, routine DBP 12.0 (13.4 to 10.7) 34.2 to 10.1
Research grade, day ABPM SBP 7.9 (9.4 to 6.4) 33.2 to 17.4
Research grade, day ABPM DBP 11.7 (12.7 to 10.8) 27.8 to 4.3
Routine clinic, day ABPM SBP 4.8 (2.9–6.7) 26.9 to 36.5
Routine clinic, day ABPM DBP 0.3 (0.9 to 1.5) 19.5 to 20.1
ABPM indicates ambulatory blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
1.34
1.31
1.14
0111.0
ABPM day SBP
Research SBP
Routine SBP
p χ2
0.005 8.5
0.001 11.5
0.07 3.5
Odds Ratio for echocardiographic LVH
Figure 2. Relationship of odds ratio for echocardiographic left
ventricular hypertrophy (LVH) and systolic blood pressure (SBP)
measured using 3 different methods. Odds ratios and their 95%
CIs are plotted together with the chi-square and P values. As
measured by the likelihood ratio test, the strength of the
relationship between SBP and LVH was stronger for daytime
ambulatory BP (ABPM) than routine SBP and LVH (P=0.032). The
strength of the relationship of LVH and research-grade SBP was
stronger than that with routine SBP (P=0.005) The strength of the
relationship of LVH and daytime ambulatory SBP was similar to
that with research-grade SBP (P=0.052).
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The results of our study suggest that there is great
variability in research-grade BP and routinely obtained BP,
even when done on the same day in the same patient;
therefore, algebraic correction of clinic BP would be insuffi-
cient for target BP in individual patients. Research-grade BP
obtained after a mandated 5 minutes of seated rest is, on
average, lower than daytime ambulatory systolic BP by
7.9 mm Hg. In contrast, routine systolic BP is 4.8 mm Hg
higher. Given the wide limits of agreement, neither is
sufficient to predict ambulatory BP. Research-grade BP is a
stronger determinant of echocardiographic LVH compared
with routine clinic BP. A limitation of this work is that it was
performed predominantly in men; however, we have little
reason to believe these data would not be applicable to
women. We did not randomize the order in which the routine
and research-grade BP measurements was made. Because
routine BP recordings were always made after the research-
grade recordings, it is expected that routine recordings would
be lower; the fact that they were higher may suggest that we
may have underestimated the height of overestimation.
Furthermore, our study was limited to patients with chronic
kidney disease.
Taken together, these findings suggest that if the SPRINT
findings were to be translated to clinic practice, the first step
would be to measure the clinic BP as was done in the trial.
Without these research-grade measurements, the likelihood
of harm (or lack of benefit) may be real.
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Figure S1: Systolic BP bias and limits of agreement for 10 subgroups 
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Figure S2: Systolic BP bias between research systolic and daytime ambulatory BP and limits of 
agreement for 10 subgroups 
